Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ pharmacokinetics
Benzimidazoles
/ administration & dosage
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cisplatin
/ administration & dosage
Cohort Studies
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Lymphatic Metastasis
Male
Maximum Tolerated Dose
Middle Aged
Paclitaxel
/ administration & dosage
Pemetrexed
/ administration & dosage
Prognosis
Tissue Distribution
MEK inhibitor
Non-small cell lung cancer
Phase I
Selumetinib
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
08
2018
accepted:
08
10
2018
pubmed:
15
10
2018
medline:
23
2
2020
entrez:
15
10
2018
Statut:
ppublish
Résumé
Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. We investigated the toxicity and the recommended phase II dose of the combination of selumetinib with two platinum based first line chemotherapy combinations in non-small cell lung cancer. Methods This was a phase I trial of escalating doses of selumetinib with carboplatin (AUC 6), paclitaxel (200 mg/m
Identifiants
pubmed: 30317534
doi: 10.1007/s10637-018-0680-z
pii: 10.1007/s10637-018-0680-z
doi:
Substances chimiques
AZD 6244
0
Benzimidazoles
0
Pemetrexed
04Q9AIZ7NO
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
498-506Références
Cancer Treat Rev. 2017 Feb;53:61-69
pubmed: 28073102
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Lancet Oncol. 2013 Jan;14(1):38-47
pubmed: 23200175
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
Mol Cancer Ther. 2007 Aug;6(8):2209-19
pubmed: 17699718
Lancet. 2009 Oct 24;374(9699):1432-40
pubmed: 19767093
Br J Cancer. 2004 Aug 2;91(3):589-98
pubmed: 15266324
Cancer Chemother Pharmacol. 2011 Feb;67(2):349-60
pubmed: 20407895
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancer Lett. 2015 Mar 1;358(1):85-91
pubmed: 25541062
Invest New Drugs. 2013 Dec;31(6):1458-65
pubmed: 24068620
Cancer Biol Ther. 2009 Mar 15;8(6):522-30
pubmed: 19305165
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
JAMA. 2017 May 9;317(18):1844-1853
pubmed: 28492898
Nature. 2012 Mar 18;483(7391):613-7
pubmed: 22425996
Lung Cancer. 2014 Apr;84(1):13-22
pubmed: 24524818
Clin Cancer Res. 2010 Mar 1;16(5):1613-23
pubmed: 20179232
J Thorac Oncol. 2010 Oct;5(10):1630-6
pubmed: 20802351
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025